Alnylam Pharmaceuticals | ALNY - Equity Capital And Reserves


Alnylam Pharmaceuticals reported $789.18M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 44.33B 2.28B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Takeda JPY 7.64T 513.39B Dec/2025
Tectonic Therapeutic USD 267.53M 16.24M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025
Xencor USD 635.59M 10.27M Dec/2025